Mirvetuximab Soravtansine Effectively Delays Disease Progression in FRα-high Ovarian Cancers, Analysis Finds

Mirvetuximab Soravtansine Effectively Delays Disease Progression in FRα-high Ovarian Cancers, Analysis Finds
ImmunoGen’s investigational therapy mirvetuximab soravtansine effectively delays disease progression in women with ovarian cancer who have high levels of the folate receptor alpha (FRα) protein, compared with chemotherapy, according to exploratory analysis on the data of the FORWARD I Phase 3 trial (NCT02631876). Previous analysis of the trial’s final data had found no significant clinical benefit of mirvetuximab over chemotherapy in this subset of patients. However, this exploratory analysis revealed that assessing FRα levels in tumor samples with the scoring method used in previous mirvetuximab studies — instead of the one employed in this trial — indeed showed statistically significant results. These findings highlight not only which women benefit most from mirvetuximab treatment, but also how to best identify them. That, in turn, led to the design of a future Phase 3 clinical trial which will evaluate mirvetuximab’s effectiveness in women with FRα-high ovarian cancer. Both the final and exploratory results of the trial were part of an oral presentation, “FORWARD I (GOG 3011): A Phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC),” given at the European Society for Medical Oncology (ESMO) Congress 2019, held Sept. 27-Oct. 1 in Barcelona, Spain. It is estimated that approximately 60% of ovarian cancers have medium-to-high levels of FRα. Mirvetuximab soravtansine is an antibody-drug conjugate that specifically targets FRα. Once the antibody binds to a cell positive for FRα, it releases a toxic compound, killing the cancer cell without harming healthy cells. The open-label, randomized,
Subscribe or to access all post and page content.